Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

ClinicalTrials.gov ID: NCT05797168

Public ClinicalTrials.gov record NCT05797168. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors

Study identification

NCT ID: NCT05797168
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: AstraZeneca; Industry
Enrollment: 506 participants

Conditions and interventions

Conditions

Interventions

Torvutatug samrotecan Drug
Saruparib Drug
Bevacizumab Drug
Carboplatin Drug
Palacaparib Drug
Pembrolizumab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 130 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 4, 2023
Primary completion: Jan 5, 2028
Completion: Jan 5, 2028
Last update posted: Jun 2, 2026

2023 – 2028

United States locations

U.S. sites: 13
U.S. states: 10
U.S. cities: 12

Facility	City	State	ZIP	Site status
Research Site	Duarte	California	91010	Recruiting
Research Site	Irvine	California	92618	Recruiting
Research Site	La Jolla	California	92093	Withdrawn
Research Site	Aurora	Colorado	80045	Recruiting
Research Site	Louisville	Kentucky	40202	Terminated
Research Site	Boston	Massachusetts	02114	Recruiting
Research Site	Detroit	Michigan	48201	Recruiting
Research Site	Columbus	Ohio	43201	Recruiting
Research Site	Portland	Oregon	97239	Recruiting
Research Site	Providence	Rhode Island	02903	Recruiting
Research Site	Providence	Rhode Island	02905	Recruiting
Research Site	Houston	Texas	77030	Recruiting
Research Site	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05797168, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 2, 2026 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05797168 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →